### Selling, general and administrative expenses reconciliation:

- **GAAP operating margin**: 55.7% 51.5% 50.5% 41.5% 49.8% 46.8%
- **Operating margin reconciliation**:
  - Non-GAAP selling, general and administrative expenses: 229,115 $       223,541 $    220,631 $    239,305 $    912,592 $       263,065 $

  (1) Amounts may not sum due to rounding

### Research and development expenses reconciliation:

- **GAAP research and development expenses**: 218,664 $       231,066 $    230,440 $    392,724 $    1,869,876 $    474,060 $
- **Research and development expenses adjustment**:
  - Non-GAAP product gross margin: 76.7% 75.9% 75.4% 75.3% 75.8% 75.7%

### Diluted earnings per share reconciliation:

- **GAAP diluted earnings per share**: 0.92 $            0.79 $         0.83 $         0.76 $          3.22 $             0.80 $
- **Stock-based compensation expenses**: 34,413 $       34,395 $    37,812 $    41,090 $         147,710 $          36,614 $

### Net income attributable to Gilead reconciliation:

- **GAAP net income attributable to Gilead**: 854,901 $       712,061 $    704,876 $    629,419 $    2,901,257 $    651,141 $
- **Stock-based compensation expenses**: 14,981 $          14,981 $    14,981 $    14,981 $         14,981 $          14,981 $

### Diluted earnings per share reconciliation:

- **GAAP diluted earnings per share**: 0.92 $            0.79 $         0.83 $         0.76 $          3.22 $             0.80 $
- **Stock-based compensation expenses**: 34,413 $       34,395 $    37,812 $    41,090 $         147,710 $          36,614 $

### Net income attributable to Gilead reconciliation:

- **GAAP net income attributable to Gilead**: 854,901 $       712,061 $    704,876 $    629,419 $    2,901,257 $    651,141 $
- **Stock-based compensation expenses**: 14,981 $          14,981 $    14,981 $    14,981 $         14,981 $          14,981 $

### Cost of goods sold reconciliation:

- **GAAP cost of goods sold**: 440,430 $       455,525 $    477,584 $    496,337 $    1,869,876 $    474,111 $
- **Acquisition-related amortization of inventory mark-up**: (4,978)       (2,042) $    (14,981) $    (14,981) $         (14,981) $          (17,407) $
- **Stock-based compensation expenses**: (2,853)       (2,267) $    (2,182) $    (1,382) $         (10,180) $          (2,644) $

### Acquisition-related amortization:

- **Acquisition-related amortization of inventory mark-up**: 0.3 % 0.1 % 0.1 % 0.1 % 0.1 % 0.1 %
- **Acquisition-related amortization of purchased intangibles**: 0.8 % 0.8 % 0.8 % 0.8 % 0.8 % 0.8 %

### Research and development expenses reconciliation:

- **GAAP research and development expenses**: 218,664 $       231,066 $    230,440 $    392,724 $    1,869,876 $    474,060 $
- **Research and development expenses adjustment**:
  - Non-GAAP product gross margin: 76.7% 75.9% 75.4% 75.3% 75.8% 75.7%

### Diluted earnings per share reconciliation:

- **GAAP diluted earnings per share**: 0.92 $            0.79 $         0.83 $         0.76 $          3.22 $             0.80 $
- **Stock-based compensation expenses**: 34,413 $       34,395 $    37,812 $    41,090 $         147,710 $          36,614 $

### Net income attributable to Gilead reconciliation:

- **GAAP net income attributable to Gilead**: 854,901 $       712,061 $    704,876 $    629,419 $    2,901,257 $    651,141 $
- **Stock-based compensation expenses**: 14,981 $          14,981 $    14,981 $    14,981 $         14,981 $          14,981 $

### Stock-based compensation expenses:

- **Stock-based compensation expenses**: 34,413 $       34,395 $    37,812 $    41,090 $         147,710 $          36,614 $

### Non-GAAP adjustment summary:

- **Cost of goods sold adjustments**: 22,815 $        19,990 $     17,709 $     16,613 $         77,127 $             20,051 $
- **Research and development expenses adjustments**: 22,169 $        23,651 $     27,261 $     161,005 $         105,013 $         6,843 $         23,651 $     27,261 $     161,005 $         105,013 $         6,843 $